What is a stock summary page? Click here for an overview.
Business Description
Affimed NV
NAICS : 325414
SIC : 2836
ISIN : NL0015001ZQ0
Description
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.94 | |||||
| Equity-to-Asset | 0.43 | |||||
| Debt-to-Equity | 0.75 | |||||
| Debt-to-EBITDA | -0.2 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -25.26 | |||||
| Beneish M-Score | 31.11 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -47.3 | |||||
| 3-Year EBITDA Growth Rate | -8.5 | |||||
| 3-Year EPS without NRI Growth Rate | -13.2 | |||||
| 3-Year FCF Growth Rate | -42.2 | |||||
| 3-Year Book Growth Rate | -22.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 34.01 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.37 | |||||
| 9-Day RSI | 43.51 | |||||
| 14-Day RSI | 39.26 | |||||
| 3-1 Month Momentum % | -12 | |||||
| 6-1 Month Momentum % | -71.1 | |||||
| 12-1 Month Momentum % | -80.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.93 | |||||
| Quick Ratio | 1.93 | |||||
| Cash Ratio | 1.49 | |||||
| Days Sales Outstanding | 1998.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.1 | |||||
| Shareholder Yield % | -41.39 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -8417.47 | |||||
| Net Margin % | -7982.22 | |||||
| FCF Margin % | -8829.87 | |||||
| ROE % | -159.79 | |||||
| ROA % | -92.43 | |||||
| ROIC % | -425.38 | |||||
| 3-Year ROIIC % | 103.13 | |||||
| ROC (Joel Greenblatt) % | -683.17 | |||||
| ROCE % | -126.8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 14.24 | |||||
| PB Ratio | 0.77 | |||||
| Price-to-Tangible-Book | 0.78 | |||||
| EV-to-EBIT | -0.02 | |||||
| EV-to-EBITDA | -0.02 | |||||
| EV-to-Revenue | 1.87 | |||||
| EV-to-Forward-Revenue | 0.49 | |||||
| EV-to-FCF | -0.02 | |||||
| Price-to-GF-Value | 2.34 | |||||
| Price-to-Median-PS-Value | 1.1 | |||||
| Price-to-Net-Current-Asset-Value | 1.39 | |||||
| Price-to-Net-Cash | 6 | |||||
| Earnings Yield (Greenblatt) % | -4355.53 | |||||
| FCF Yield % | -564.78 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Affimed NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.877 | ||
| EPS (TTM) (€) | -4.57 | ||
| Beta | 1.19 | ||
| 3-Year Sharpe Ratio | -1.37 | ||
| 3-Year Sortino Ratio | -1.48 | ||
| Volatility % | 72.37 | ||
| 14-Day RSI | 39.26 | ||
| 14-Day ATR (€) | 0.011187 | ||
| 20-Day SMA (€) | 0.9597 | ||
| 12-1 Month Momentum % | -80.39 | ||
| 52-Week Range (€) | 0.89 - 7.08 | ||
| Shares Outstanding (Mil) | 16.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Affimed NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Affimed NV Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Affimed NV Frequently Asked Questions
What is Affimed NV(STU:A28A)'s stock price today?
The current price of STU:A28A is €0.96. The 52 week high of STU:A28A is €7.08 and 52 week low is €0.89.
When is next earnings date of Affimed NV(STU:A28A)?
The next earnings date of Affimed NV(STU:A28A) is 2025-03-28 Est..
Does Affimed NV(STU:A28A) pay dividends? If so, how much?
Affimed NV(STU:A28A) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers